Search results
Found 10486 matches for
Davies Group: Genomics and Clinical Genome Editing
We are primarily interested in understanding how the genome functions and to leverage this to develop novel genome editing based cellular therapies
Patel Group: Two tier protection and metabolic genotoxicity during blood production
We study endogenous DNA damage caused by metabolites and their impact on the function of vertebrate stem cells and the ageing process
Sims Group: Computational Genomics
We are a computational biology research group using genomic and functional genomic data to study transcriptional regulation, with projects spanning from neuroscience to musculoskeletal biology.
Sauka-Spengler Group: Gene Regulatory Networks in Development and Disease
We focus on systems level “big picture” approaches to understand gene regulation and build gene regulatory networks during development and disease in zebrafish, chick, lamprey and human models.
Hughes Group: Genome Biology
Using genomics, computational and synthetic biology approaches to understand how genes are regulated in health and disease.
Nerlov Group: Hematopoietic Stem Cell Genetics
Hematopoietic stem cell (HSC) transplantation is the only stem cell therapy in routine clinical use, and it is also the cell type that gives rise to most blood cancers. We use single cell biology and genetics to understand how hematopoietic stem cells normally sustain blood formation, and how this process is altered during ageing and when leukemia develops.
Ho Group: Translational Lung Immunology
Immune mechanisms of lung injury, regeneration and fibrosis; identifying new therapeutic targets, and improved treatment for idiopathic pulmonary fibrosis and sarcoidosis. See our Spotlight video - https://youtu.be/Dj0uNQgA1Fs
Neuromuscular Disorders
We work to translate an understanding of the molecular mechanisms of disease at the neuromuscular synapse into treatments. Our work led us to be commissioned to provide a National Advisory and Diagnostic Service for congenital myasthenic syndromes.
Ovarian Cancer
Ovarian cancer is one of the most lethal gynaecological malignancies predominantly because of late presentation and chemotherapy resistance. Recent advances in single cell RNA sequencing and DNA sequencing have made it possible to obtain unprecedented insights into tumour biology. Our lab has developed sequencing strategies and analysis algorithms to accelerate the mechanistic understanding of ovarian cancer initiation, progression and chemotherapy resistance. The use of these technologies and our access to patients recruited in clinical research studies provide exciting opportunities for addressing key questions in ovarian cancer such as a) understanding the cell of origin of ovarian cancer, b) characterising the tumour initiating cells in minimal residual disease and c) understanding T cell immune responses against ovarian cancer initiation and progression.
Milne Group: Epigenetic Control of Gene Expression in Leukaemia and Haematopoiesis
Aberrant epigenetic changes are a driving force in many human cancers. The focus of our lab is centred on understanding how epigenetics impacts gene regulation so that this information can potentially be used to develop new therapeutic strategies.
Higgs Group: Laboratory of Gene Regulation
We use state-of-the-art laboratory and computational approaches to understand how mammalian genes are switched on and off during development and differentiation and how this goes awry in human genetic diseases.
Bannard Group: B Cell Immunology
We study the cellular and molecular events responsible for shepherding the development of protective antibodies during infection and after immunisation. Our main focus is the germinal centre reaction.
Jackson Group: Lymphatic Trafficking Research Group
We focus on the mechanisms controlling the migration of leucocytes and tumour cells via lymph in health and disease.
Oxford Centre for Neuroinflammation
We bring together biomedical, analytical and clinical expertise to shed new light on the causes that underpin neurodegenerative diseases.
Goriely Group: Clinical genetics
We are using a human genetic approach that relies on the latest developments of Next Generation Sequencing technology to study the intimate relationship that exists between the occurrence of new mutations and the regulation of cell fate choices in the male germline. Because life-long production of sperm is supported by regular divisions of so-called spermatogonial stem cells, each one of us acquire ~30-100 new mutations in our genome, the majority of which is paternal in origin.
Wilkie Group: Clinical Genetics
The ability to sequence whole exomes and genomes of individual people has revolutionised our ability to explore the full spectrum of genetic mutations causing serious human diseases. Working closely with the craniofacial teams based in Oxford and other UK units, we specialise in the application of these methods to children born with a serious malformation of the skull termed craniosynostosis.
Davis Group: T-cell Biology
We are interested in how lymphocytes decide to mount immune responses against, for example, tumours. This involves trying to understanding how leukocyte receptors, such as the T-cell receptor and immune checkpoints, are triggered.